nature neurOSCIenCe a r t I C l e S The behavioral and psychoactive effects of cannabinoids are mediated by activation of brain cannabinoid receptors 1,2 . Two major cannabinoid receptors (CB 1 and CB 2 ) have been identified. Given that CB 1 receptors are highly expressed in the brain 2,3 and CB 2 receptors are found primarily in the periphery 4, 5 , it has generally been believed that the behavioral and psychotropic effects of cannabinoids are CB 1 -mediated 1,2 and that CB 2 receptor ligands have no psychoactive effects 6 . However, the purported lack of brain CB 2 receptors has been challenged by recent reports of low densities of CB 2 receptors on microglia 7 and neuronal 8-11 cells in several brain regions, including the anterior olfactory nucleus, cerebral cortex, cerebellum, hippocampus, striatum and brainstem. Furthermore, activation of CB 2 receptors by 2-arachidonoylglycerol, JWH015 or JWH133 inhibits locomotion 10,11 , morphine-6-glucuronideinduced emesis 11 and neuropathic pain 12,13 , while stimulating neural progenitor proliferation 14 and producing neuroprotective effects 15, 16 . More recent studies have suggested that CB 2 receptor activation inhibits neuronal firing in dorsal-root ganglia and spinal cord 17, 18 and GABAergic transmission in rat cerebral cortex 19 . These data indicate that functional CB 2 receptors may be expressed on CNS neuronal cells, prompting us to re-examine the role of CB 2 receptors in drug reward and addiction. To this end, we used highly selective CB 2 receptor agonists and antagonists, combined with specific CB 1 receptor knockout (CB 1 −/− ) and CB 2 receptor knockout (CB 2 −/− ) mice, to investigate the possible involvement of brain CB 2 receptors in cocaine's behavioral and neurochemical effects.
a r t I C l e S
The behavioral and psychoactive effects of cannabinoids are mediated by activation of brain cannabinoid receptors 1, 2 . Two major cannabinoid receptors (CB 1 and CB 2 ) have been identified. Given that CB 1 receptors are highly expressed in the brain 2, 3 and CB 2 receptors are found primarily in the periphery 4, 5 , it has generally been believed that the behavioral and psychotropic effects of cannabinoids are CB 1 -mediated 1, 2 and that CB 2 receptor ligands have no psychoactive effects 6 . However, the purported lack of brain CB 2 receptors has been challenged by recent reports of low densities of CB 2 receptors on microglia 7 and neuronal [8] [9] [10] [11] cells in several brain regions, including the anterior olfactory nucleus, cerebral cortex, cerebellum, hippocampus, striatum and brainstem. Furthermore, activation of CB 2 receptors by 2-arachidonoylglycerol, JWH015 or JWH133 inhibits locomotion 10, 11 , morphine-6-glucuronideinduced emesis 11 and neuropathic pain 12, 13 , while stimulating neural progenitor proliferation 14 and producing neuroprotective effects 15, 16 . More recent studies have suggested that CB 2 receptor activation inhibits neuronal firing in dorsal-root ganglia and spinal cord 17, 18 and GABAergic transmission in rat cerebral cortex 19 . These data indicate that functional CB 2 receptors may be expressed on CNS neuronal cells, prompting us to re-examine the role of CB 2 receptors in drug reward and addiction. To this end, we used highly selective CB 2 receptor agonists and antagonists, combined with specific CB 1 receptor knockout (CB 1 −/− ) and CB 2 receptor knockout (CB 2 −/− ) mice, to investigate the possible involvement of brain CB 2 receptors in cocaine's behavioral and neurochemical effects.
RESULTS

JWH133 inhibits intravenous cocaine self-administration
To determine whether CB 2 receptor activation alters intravenous cocaine self-administration, we used JWH133, a highly selective CB 2 receptor agonist (200-fold selectivity for CB 2 versus CB 1 ) 20, 21 , and AM630, a highly selective CB 2 receptor antagonist (160-fold selectivity for CB 2 versus CB 1 ) 20, 21 , as pharmacological tools. We found that over 50% of wild-type (20 of 34) and CB 2 −/− (22 of 36) mice, but only about 30% of CB 1 −/− (10 of 36) mice, acquired stable intravenous cocaine self-administration, defined as 20 or more infusions per 3-h session, with a regular pattern of self-administration achieved after 10 d of training (Supplementary Fig. 1 ). Notably, CB 1 −/− mice displayed a significant reduction in both the total number (P < 0.05, two-way ANOVA; Supplementary Fig. 1a ) and rate (infusions per h, P < 0.05; Supplementary Fig. 1b ) of cocaine infusions on days 1-5, as compared with wild-type or CB 2 −/− mice. In addition, the majority of CB 1 −/− mice (7 of 10) displayed a distinct 'burst-like' drug-taking pattern, with long inter-burst intervals, whereas wild-type and CB 2 −/− mice displayed evenly paced drug-taking without a significant difference between the two strains ( Supplementary Fig. 1c ). These findings suggest that deletion of CB 1 receptors may lower cocaine's rewarding efficacy, leading to a compensatory increase in drug intake during each individual drug-taking episode. This is further supported by the finding that CB 1 −/− mice displayed a significant reduction in break-point level for cocaine self-administration under progressive-ratio reinforcement, as compared with wild-type mice (P < 0.05; Supplementary Fig. 1d ). Given that the progressive-ratio a r t I C l e S break point, defined as the maximal work performed by the animal to get a cocaine infusion, is cocaine dose dependent and positively correlated to reward strength 22 , the reduction in progressive-ratio break point that we observed in CB 1 −/− mice suggests that there is a reduction in cocaine's reward strength and/or motivation for cocainetaking behavior. This is consistent with previous findings that CB 1 receptor deletion impairs cocaine's rewarding, locomotor-stimulating and dopamine (DA)-elevating effects 23, 24 .
Intraperitoneal administration of JWH133 (10 or 20 mg per kg of body weight) produced a significant and dose-dependent reduction in cocaine self-administration and cocaine intake in both wild-type (P < 0.001, one-way ANOVA) and CB 1 −/− (P < 0.05) mice, but not in CB 2 −/− mice (P = 0.58; Fig. 1a ). This inhibition lasted for no longer than 24 h after JWH133 administration (20 mg per kg; Fig. 1b,c) . Pretreatment with AM630, a selective CB 2 receptor antagonist, but not with AM251, a selective CB 1 receptor antagonist 25 , significantly attenuated JWH133-induced inhibition of cocaine self-administration (P < 0.001, one-way ANOVA; Fig. 1d ). This suggests that JWH133's attenuating effect is mediated by activation of CB 2 , rather than by CB 1 , receptors. This conclusion is further supported by the finding that systemic administration of GW405833 (3 or 10 mg per kg, intraperitoneal), another highly selective, but structurally distinct, CB 2 receptor agonist 26 , also inhibited cocaine self-administration in wild-type mice (P < 0.001; Fig. 2a) .
To determine whether JWH133-induced attenuation of cocaine self-administration was a result of a reduction in cocaine's rewarding efficacy, we studied JWH133's effect on intravenous cocaine selfadministration under progressive ratio reinforcement. We found that systemic administration of JWH133 (10, 20 mg per kg, intraperitoneal) significantly lowered the progressive-ratio break point for cocaine selfadministration in wild-type mice (P < 0.01; Fig. 2b ), suggesting that there was a reduction in cocaine's reward strength and/or motivation for drug-taking behavior after JWH133 administration. We previously showed that CB 1 receptor blockade by AM251 substantially lowered the progressive-ratio break point for cocaine self-administration in rats 27 . We therefore also tested AM251 and found that AM251 (3 mg per kg) lowered the progressive-ratio break point for cocaine selfadministration in wild-type mice (P < 0.001; Fig. 2b ). These data suggest that the JWH133-induced reduction in cocaine self-administration resulted from a reduction in cocaine's rewarding efficacy.
JWH133 inhibits cocaine intake via brain CB 2 receptors
To further determine whether JWH133's action was mediated by activation of brain or peripheral CB 2 receptors, we first studied the effects (f) IntraNAc administration of JWH133 (3 µg per side) had no effect on cocaine self-administration in CB 2 −/− mice (F 1,10 = 2.37, P = 0.15). Data are means ± s.e.m. *P < 0.05, ***P < 0.001, compared with vehicle control group. 1 1 6 2 VOLUME 14 | NUMBER 9 | SEPTEMBER 2011 nature neurOSCIenCe a r t I C l e S of intranasal microinjections of JWH133 on intravenous cocaine selfadministration. Extensive studies have shown that a wide variety of compounds that cannot penetrate the blood-brain barrier can be delivered directly from nose to brain 28 . We found that intranasal microinjections of JWH133 (50 and 100 µg per 10 µl per side) dose-dependently inhibited intravenous cocaine self-administration (Fig. 2c) . To explore the possibility that the effects of intranasal JWH133 might be mediated by drug absorption into the nasal vasculature with subsequent venous delivery of drug to pharmacological site(s) of action, we observed the effects of intravenous injection of the same micro-quantities of JWH133 as were administered intranasally on cocaine self-administration. We found that intravenous microinjections of JWH133 (100 and 200 µg) had no effect on cocaine self-administration (Fig. 2d) . These data suggest that intranasal JWH133-induced pharmacological effects are mediated by activating brain rather than peripheral CB 2 receptors.
To further explore this issue, we observed the effects of local administration of JWH133 into the nucleus accumbens (NAc) on cocaine selfadministration. We found that intra-NAc microinjections of JWH133 (0.3, 1 and 3 µg per side) significantly and dose-dependently inhibited cocaine self-administration in wild-type mice (P < 0.05, one-way ANOVA; Fig. 2e ), but not in CB 2 −/− mice (P > 0.05; Fig. 2f ). This inhibition was blocked by intra-NAc co-administration of AM630 (3 µg per side).
JWH133 itself has no reinforcing or aversive effects
We further examined whether JWH133 itself has cocaine-like rewarding effects. To address this issue, we first trained mice to acquire stable cocaine self-administration, and then cocaine was replaced by JWH133 (1 mg per kg per infusion) or vehicle. We found that neither JWH133 nor vehicle sustained stable self-administration in mice that were previously trained to self-administer cocaine ( Supplementary  Fig. 2a ). In fact, the self-administration behavior underwent gradual extinction over the 5 d of substitution testing. This extinction pattern was essentially identical to that seen when vehicle was substituted for cocaine. However, when JWH133 or vehicle was replaced by cocaine, self-administration behavior returned to the levels observed during stable cocaine self-administration.
In addition, we also found that cocaine (10 and 20 mg per kg, intraperitoneal) produced a substantial and robust conditioned place preference, whereas JWH133, at the same doses, produced neither conditioned place preference nor place aversion in wild-type mice (Supplementary Fig. 2b ). These findings suggest that JWH133 has no cocaine-like reinforcing or aversive effects in mice.
JWH133 inhibits cocaine-enhanced locomotion
To determine whether JWH133's effect on cocaine self-administration generalizes to other cocaine actions, we investigated the effects of JWH133 on cocaine-enhanced locomotion. Systemic administration of cocaine (10 mg per kg) produced a robust increase in locomotion in all three mouse strains (Fig. 3) . Pretreatment with JWH133 (10 and 20 mg per kg, 30 min before cocaine) dosedependently attenuated cocaine-enhanced locomotion in wild-type (Fig. 3a) and CB 1 −/− (Fig. 3b) mice, but not in CB 2 −/− (Fig. 3c) mice. (Fig. 4a) , suggesting that there is an effect mediated by activation of CB 2 receptors. As the same doses of JWH133 alone did not alter locomotor performance on a fast-running rotarod device in all three mouse strains ( Supplementary Fig. 3 ), we infer that JWH133's inhibition of cocaine self-administration or locomotion is not produced by nonspecific impairment of locomotor capacity. To further determine whether such locomotor inhibition is mediated by activation of brain CB 2 receptors, we observed the effects of intra-NAc JWH133 and/or AM630 on locomotion. We found that intra-NAc microinjections of JWH133 (1 and 3 µg per side) significantly inhibited locomotion in wild-type and CB 1 −/− mice (P < 0.05), but not in CB 2 −/− mice (Fig. 4b) , in a dose-dependent manner similar to systemic administration (Fig. 4a) . Notably, systemic administration of AM630 did not alter locomotion in any of the mouse strains that we tested (Fig. 4c) . However, when locally administered into the NAc, AM630 (1, 3 and 10 µg per side) significantly increased locomotor activity (P < 0.05; Fig. 4d ) in wild-type and CB 1 −/− mice, but not in CB 2 −/− mice. These data suggest that CB 2 receptors may tonically modulate locomotion. A higher level of AM630 in the brain, achieved by local rather than by systemic administration, appears to be required to block endocannabinoid action on brain CB 2 receptors.
JWH133 inhibits cocaine-enhanced extracellular NAc DA Given the crucial role of the mesolimbic DA system in cocaine self-administration and modulation of locomotion 29 , we further investigated the effects of JWH133 on basal and cocaine-enhanced DA in the NAc by in vivo microdialysis. We did not see significant differences in basal levels of extracellular NAc DA between wild-type (0.25 ± 0.05 nM, n = 26) and CB 2 −/− (0.24 ± 0.05 nM, n = 22) mice (P > 0.05; Supplementary Fig. 4 ). However, CB 1 −/− mice displayed a significant basal reduction (0.13 ± 0.04 nM, n = 28), as compared with wild-type mice (P < 0.05; Supplementary Fig. 4) . Consistent with our findings in cocaine self-administration and locomotion, systemic administration of JWH133 (3, 10 and 20 mg per kg, intraperitoneal) also significantly (P < 0.001) and dose-dependently lowered extracellular NAc DA in wild-type (Fig. 5a) and CB 1 −/− (Fig. 5b) mice, but not in CB 2 −/− (Fig. 5c) mice. This reduction in NAc DA was blocked by AM630 (10 mg per kg, intraperitoneal) in CB 1 −/− mice (Fig. 5b) , suggesting that JWH133's DA-inhibiting effect is mediated by activation of CB 2 receptors. Moreover, pretreatment with the same doses of JWH133 also significantly attenuated (P < 0.05) cocaineenhanced NAc DA in wild-type (Fig. 5d) and CB 1 −/− (Fig. 5e) mice, but not in CB 2 −/− (Fig. 5f) mice. To determine whether this inhibition is mediated by activation of brain or peripheral CB 2 receptors, we also observed the effects of intranasal or intra-NAc local administration of JWH133 on extracellular DA. We found that intranasal administration of JWH133 (100 µg per nostril) produced a robust reduction in extracellular NAc DA in wild-type and CB 1 −/− mice, but not in CB 2 −/− mice (Fig. 6a) . Similarly, intra-NAc local perfusion of JWH133 (1-1,000 µM) robustly lowered extracellular DA in both wild-type and CB 1 −/− mice, but not in CB 2 −/− mice (Fig. 6b) . In fact, an unexpected increase in extracellular DA was observed in CB 2 −/− mice after local administration of JWH133. The underlying mechanisms are unclear. One possibility is that JWH133 may bind to other (non-CB 2 ) receptors *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** ** *** *** *** *** ** ** ** ** ** ** ** . Data are means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, compared with pre-drug baseline. # P < 0.05, ## P < 0.01, compared with vehicle treatment group. 1 1 6 4 VOLUME 14 | NUMBER 9 | SEPTEMBER 2011 nature neurOSCIenCe a r t I C l e S in CB 2 −/− mice, producing an increase in extracellular DA. Congruent with this finding, intra-NAc local perfusion of AM630 (1, 10 and 100 µM) elevated extracellular DA in a concentrationdependent manner in both wild-type and CB 1 −/− mice, but not in CB 2 −/− mice (Fig. 6c) , suggesting that endocannabinoids tonically modulate NAc DA release by activating CB 2 receptors in the brain. Furthermore, AM630-enhanced extracellular DA appeared more robust in CB 1 −/− mice than in wild-type mice (Fig. 6c) , suggesting that there is a higher endocannabinoid basal activity on CB 2 receptors in the brains of CB 1 −/− mice. Moreover, intra-NAc local perfusion of AM630 also blocked the reduction in extracellular NAc DA that was produced by systemic administration of JWH133 in wild-type and CB 1 −/− mice (Fig. 6c,d) , suggesting that JWH133-induced inhibition of DA release is mediated by activation of NAc CB 2 receptors. The microdialysis probes and microinjection cannulae were located in the NAc (Supplementary Fig. 5 ).
DISCUSSION
We found that systemic administration of the CB 2 receptor agonist JWH133 robustly and dose-dependently inhibited intravenous cocaine self-administration under both fixed ratio 1 (FR1) and progressive ratio reinforcement and inhibited cocaine-enhanced locomotion and extracellular NAc DA in wild-type and CB 1 −/− mice, but not in CB 2 −/− mice. This effect was mimicked by GW405833 (another selective CB 2 receptor agonist) and blocked by AM630, a selective CB 2 receptor antagonist, but not by AM251, a selective CB 1 receptor antagonist, suggesting that the effect is mediated by activation of CB 2 receptors. Furthermore, intranasal microinjections of JWH133, but not intravenous injections of the same micro-quantities of JWH133 as were injected intranasally, robustly and dose-dependently inhibited intravenous cocaine self-administration, suggesting that the effect was mediated by activation of brain and not peripheral CB 2 receptors. This is further supported by the finding that local intra-NAc administration of JWH133 robustly inhibited cocaine self-administration in a dose-dependent manner, an effect that was blocked by intra-NAc co-administration of AM630. In addition, intra-NAc local administration of JWH133 dose-dependently lowered, whereas AM630 elevated, basal levels of locomotion and extracellular NAc DA. Intra-NAc local perfusion of AM630 blocked the reduction in cocaine self-administration and NAc DA produced by systemic administration of JWH133. These data suggest that both the behavioral and neurochemical effects of JWH133 are mediated by activation of brain CB 2 receptors.
Systemic administration of AM630 did not alter, whereas intra-NAc local administration of AM630 elevated, extracellular DA and locomotion, suggesting that local AM630 administration is more effective than systemic administration. This may be related to AM630's relatively poor pharmacokinetic properties and/or blood-brain barrier passage. In addition, intra-NAc AM630 robustly elevated extracellular DA and locomotion, but did not alter cocaine self-administration. This may be related to previous findings that locomotion is largely DA dependent 30 , whereas cocaine self-administration is dependent on both DA and non-DA mechanisms 31 . Pharmacological blockade of NAc CB 2 receptors elevated, whereas genetic deletion of CB 2 receptors did not alter, basal extracellular DA in the NAc, for reasons that are unclear. One possibility is that CB 2 receptor deletion-induced disinhibition of NAc DA release may be compromised by actions in other brain loci that modulate the mesolimbic DA system. Another possibility is that neuroadaptative processes may antagonize CB 2 receptor inactivation-induced DA neuronal disinhibition after CB 2 receptor deletion. Whatever the exact mechanism(s), our data strongly suggest that brain CB 2 receptors functionally modulate the mesolimbic DA system and DA-related functions. Activation of brain CB 2 receptors by JWH133 inhibited both the behavioral and neurochemical effects of cocaine. Given that JWH133 neither altered locomotor performance, as assessed by the rotarod test, nor produced drug rewarding or aversive effects, as assessed by intravenous self-administration and conditioned place preference, JWH133-induced inhibition of cocaine self-administration is most likely mediated by attenuation of cocaine's rewarding efficacy secondary to the reduction in cocaine-enhanced NAc DA rather than by nonspecific locomotor impairment or malaise.
We fully recognize that these findings challenge the currently accepted opinion that selective CB 2 receptor agonists have no CNS effects. This opinion is largely based on previous reports that the Wild type (n = 7)
Wild type (n = 7)
Wild type (n = 5)
a b c d Figure 6 Effects of intranasal or intra- 1 −/− mice. Data are means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, compared with pre-drug baseline. a r t I C l e S selective CB 2 receptor agonist AM1241 neither inhibits locomotion or rotarod performance, nor produces catalepsy or hypothermia in rats or mice 32 . In addition, AM1241 also fails to alter brain functional activity, as assessed by pharmacological magnetic resonance imaging 33 . The ineffectiveness of AM1241 may be related to the relatively lower doses (30 µg per kg to 3.3 mg per kg) used in those studies, relatively poor selectivity and species differences in CB 2 receptor response to AM1241 (refs. 34-36) . For example, AM1241 is reported to act as a full or partial agonist at human CB 2 receptors 35 , whereas it acts as an inverse agonist at rodent CB 2 receptors 36 . Furthermore, the analgesic effects produced by AM1241 are reported to be blocked by the opioid receptor antagonist naloxone 37 , suggesting that AM1241 may interact with other non-cannabinoid receptors. However, the CB 2 receptor agonist GW405833, at high doses (30-100 mg per kg), produces substantial CNS effects, such as analgesia, sedation and catalepsy 26 , consistent with our finding that GW405833 (3-10 mg per kg) substantially inhibited cocaine self-administration in mice.
The presence of CB 2 receptors in the CNS, particularly on neurons, has been the subject of much debate 10, 38 . Previous studies using in situ hybridization and northern blot assays failed to detect CB 2 receptor mRNA in brain 5, 39, 40 . However, recent studies with more sensitive reverse transcription PCR and immunolabeling techniques have found substantial CB 2 receptor expression in microglia and subpopulations of neuronal cells in brain [7] [8] [9] [10] [11] . Using highly sensitive and specific Taqman probes, we recently identified two CB 2 receptor isoforms (CB 2A and CB 2B ) in both brain and peripheral tissues, which show substantial species differences in both structure and expression between humans, rats and mice 41 . It is now well accepted that CB 2 receptors are expressed on microglia and a subset of neurons, with levels increasing under certain pathological conditions, such as neuroinflammation and brain injury 38 . There are two possible explanations for our findings. First, a low density of CB 2 receptors may be expressed on mesolimbic DA neurons. As CB 2 receptors are G i/o coupled 42 , activation of CB 2 receptors on DA neurons in the midbrain ventral tegmental area (VTA) may directly inhibit VTA DA neurons and decrease NAc DA release, and therefore inhibit intravenous cocaine self-administration and cocaine-enhanced locomotion, as we observed. Although direct evidence of CB 2 receptor expression in the mesolimbic DA neurons is currently lacking, functional CB 2 receptors are found on other neurons. For example, CB 2 receptor mRNA is expressed on striatal GABAergic neurons in non-human primates 43 , and activation of CB 2 receptors inhibits GABAergic neurotransmission in the medial entorhinal cortex of the rat 19 . In addition, CB 2 receptors are also found on neurons in the dorsal root ganglion and spinal cord 44, 45 , and activation of CB 2 receptors on dorsal root ganglion-spinal cord neurons inhibits neuronal response to noxious stimuli 45, 46 , thereby contributing to the antinociceptive effects of CB 2 receptor agonists 47 . The second possibility is that activation of CB 2 receptors located on microglial cells or astrocytes in the VTA and/or NAc may indirectly inhibit NAc DA release by releasing cytokines and inflammatory factors 48 , thereby inhibiting cocaine self-administration and cocaine-enhanced locomotion as we observed.
Whatever the mechanisms, our findings suggest for the first time, to the best of our knowledge, that activation of brain CB 2 receptors inhibits cocaine's rewarding and psychomotor-stimulating effects, which is congruent with a rapidly expanding corpus of published reports implicating brain CB 2 receptors in modulating a variety of CNS functions, such as locomotion 10 , pain 13, 47 , emesis 11 , neurogenesis 14 and neuroprotection 15 . This finding not only challenges current views that CB 2 receptors are absent from the CNS and that CB 2 receptor ligands lack CNS effects, but also suggests that brain CB 2 receptors may be a target for the pharmacotherapy of drug abuse and addiction.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
